Europe's drug regulator said it had started a real-time review of AstraZeneca's antibody-based Covid-19 therapy, the first protective shot other than vaccines against coronavirus.
The decision by the human medicines committee of the European Medicines Agency (EMA) to begin the rolling review was based on early results from clinical studies, the regulator said.
It did not say when a conclusion was expected.
The move to start a real-time review, so called because data is evaluated as it is made available, came roughly a week after the Anglo-Swedish drugmaker sought emergency approval from US authorities, Reuters reports.
